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A survey of the prescription of the novel anticonvulsants lrunotrigine, vigabatrin, gabapentin and topiramate was carried out in 
an outpatient setting to investigate the outcome of prescription and factors affecting response. One hundred and fifty randomly 
selected patient notes were analysed retrospectively. Drug continuation and seizure freedom were used as measures of response. 
Twenty-nine percent of patients had a brain lesion, 14% a psychiatric disorder, 7% neonatal seizures, 21% a family history of 
epilepsy and 15% a learning disability. On average at the moment of initiation of the novel anticonvulsant the patients had had a 
diagnosis of epilepsy for 18 years, were 33 years old, had 19 seizures per month and had previously used two drugs which failed 
to control their epilepsy. The first novel anticonvulsant was in 55% of cases lamotrigine, in 43% vigabatrin and in 1% gabapentin. 
The overall percentage of patients who stayed on their first novel anticonvulsant was 55%, and 17% became seizure-free. No 
factors were found to influence the response in terms of drug continuation. For seizure freedom, the presence of a psychiatric 
disorder and partial seizures predicted a significantly poorer response. Length of seizure disorder, seizure frequency at initiation, 
the number of previously used failed drugs and the total number of chugs previously used were all significantly lower in the 
seizure-free group. 
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INTRODUCTION 
Four novel anticonvulsant drugs, vigabatrin, lamot- 
rigine, gabapentin and topiramate, have been intro- 
duced in the UK in 1989, 1992, 1994 and 1996, re- 
spectively. These new drugs are indicated for add-on 
treatment of partial and secondary generalized (tonic- 
clonic) seizures which are inadequately controlled by 
the standard antiepileptic drugslA. This indication in- 
cludes up to 30% of the population with epilepsy5. 
With additional indications, in the case of lamotrigine, 
for monotherapy and the treatment of Lennox Gastaut 
syndrome. 
In a review of the randomized controlled trials of 
add-on treatments with these drugs, they were con- 
cluded to be significantly better than placebos at re- 
ducing seizure frequency, but a conclusive indication 
of difference in efficacy and tolerability could not be 
found6v7. In addition, the question still remains as to 
whether the new antiepileptic drugs affect the long- 
1059-l 311/98/050379 + 05 $12.00/O 
term prognosis of refractory epilepsy8*9. Walker et al8 
showed that after 6-8 years of follow-up, of 253 pa- 
tients with severe refractory epilepsy who participated 
in a trial of add-on treatment of vigabatrin or lamot- 
rigine, 73% were withdrawn from their trial drugs and 
only 1% became seizure-free’. However, no investiga- 
tion of patient characteristics affecting these outcome 
measures was carried out. 
In order to address this problem, we undertook a 
study to investigate, first, the outcome of the prescrip- 
tion of novel anticonvulsants in an outpatient setting 
and, second, to elucidate factors which may predict re- 
sponse to novel anticonvulsant medication. 
MATERIALS AND METHODS 
All the patients in this study were referred to the 
Epilepsy Unit of the University Hospital of Wales, 
Cardiff, Wales, UK. This unit is both a specialist re- 
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ferral centre for patients with epilepsy in Wales and a 
direct referral centre for primary care physicians. Data 
were obtained by review of the notes. A non-biased 
randomized method was used for sampling the notes. 
A pilot study of 15 notes was performed to verify the 
methodology. Of the 2560 patients’ notes held in the 
unit, 640 were studied. Patients were included in the 
study if they had used at least one of the novel anticon- 
vulsants vigabatrin, lamotrigine, gabapentin or topira- 
mate. They had to have used the drugs for at least 3 
months, unless withdrawn within this period, to be in- 
cluded in the study. 
Our outcome measures of response were continua- 
tion of the drug and seizure freedom. Seizure freedom 
was recorded if a patient did not have a seizure for a 
period longer than 3 months until the end of follow-up. 
The following patient characteristics were predicted 
to have an influence on the outcome: age at initiation, 
age at first seizure, length of seizure disorder, seizure 
frequency at initiation, the number of previously used 
failed drugs and the total number of drugs prescribed, 
as well as type of seizure disorder (primary general- 
ized epilepsy or partial epilepsy), sex, the presence of 
a psychiatric disorder, learning disability, a structural 
brain lesion, neonatal seizures and a family history of 
epilepsy. 
If no mention was made of the latter factors, they 
were considered to be absent. Seizure frequency was 
recorded as the number of seizures per month. The 
recording of a family history of epilepsy was restricted 
to first- and second-degree relatives. A structural brain 
lesion was defined as a deformity of the brain which 
presumably generates the epileptic activity. 
All previously prescribed ‘classic’ anticonvulsants, 
as well as the maximum daily dosages reached, were 
recorded. If a novel anticonvulsant was withdrawn the 
reason for withdrawal and the time period the drug was 
used for were recorded. 
Statistics 
Data were coded and analysed on SPSS for Windows. 
chi-squared statistics were used to compare the effects 
of dichotomous variables. The non-parametric Mann- 
Whitney U-test (or the Wilcoxon signed-rank test) was 
applied to compare continuous variables. 
RESULTS 
Patient characteristics 
A total of 150 patients (81 female, 69 male) from the 
640 notes (23%) were found to have had a novel anti- 
convulsant prescribed. The mean age of the patients 
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was 38 years (SD = 13). The majority of the pa- 
tients had partial seizures with secondary generaliza- 
tion (56%), 25% a primary generalized disorder and 
18% partial seizures without secondary generalization. 
Twenty-nine percent of patients had a brain lesion, 
14% a psychiatric disorder, 7% neonatal seizures, 2 1% 
a family history of epilepsy and 15% a learning disabil- 
ity. Of the 43 patients with a brain lesion, eight had suf- 
fered head injury, seven meningitis or encephalitis, five 
birth trauma, five a brain tumour, four hydrocephalus, 
three had developed epilepsy following neurosurgery, 
two an arteriovenous malformation, two a cerebrovas- 
cular accident, two microcephalus, two temporal scle- 
rosis, one multiple sclerosis, one an arachnoid cyst and 
one a cerebral abscess. 
Of the 21 patients with a psychiatric disorder, 11 suf- 
fered from depression, five from an anxiety disorder, 
one a bipolar disorder, two alcoholism, one a schizo- 
affective disorder, and one a borderline personality. 
The average age at first seizure was 15 years. On 
average, at the moment of initiation of the novel anti- 
convulsant the patients had had a diagnosis of epilepsy 
for 18 years, were 33 years old and had 19 seizures 
per month (median = 6). Of the 123 patients who had 
their seizure frequency recorded, 20% had more than 
one seizure per day, 44% had one to six seizures per 
week, 25% one to three a month, 2% one to 11 a year 
and 7% of the patients were seizure-free at moment of 
initiation. The patients had used, on average, two drugs 
previously that had failed to control their epilepsy. 
Previous anticonvulsants included carbamazepine 
(89%), valproate (81%), phenytoin (60%), primidone 
(290/o), phenobarbitone (27%), clobazam (16%), clon- 
azepam (11%) and ethosuximide (9%). 
The first novel anticonvulsant was in 55% of cases 
lamotrigine, 43% vigabatrin and 1% gabapentin. Fig- 
ure 1 depicts the distribution of lamotrigine, vigabatrin, 
gabapentin and topiramate in relation to the order these 
drugs were prescribed. The mean number of novel anti- 
convulsants prescribed was 1.6. 
As a first-order novel anticonvulsant 76% (n = 38) 
of the patients with primary generalized epilepsy re- 
Order of new anticonvulsant 
Fig. 1: The distribution of lamotrigine (m), vigabatrin (m), 
topiramate ( ) and gabapentin (0) in relation to the order 
these drugs were prescribed. 
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ceived lamotrigine and 24% (n = 38) vigabatrin. 
Of the patients with partial or secondary generalized 
seizures 50% received vigabatrin as a first-order drug, 
48% lamotrigine and 2% gabapentin. 
Response 
The overall percentage of patients who stayed on their 
first novel antiepileptic drug was 55%, and 56% (n = 
63) of patients stayed on their second novel drug. Fig- 
ure 2 shows the frequency of withdrawal and contin- 
uation of the drug in relation to the order of prescrip- 
tion. Reasons for withdrawal were lack of efficacy 55% 
(n = 66), side effects 36% (n = 66), patient initiated 
8% (n = 66) and seizure freedom 1% (n = 66). Fig- 
ure 3 illustrates the percentage of the patients staying 
on the drug for 1 year from the time of prescription 
(t = 0). 
The mean follow-up time of the patients staying on 
the first novel anticonvulsant prescribed was 4.4 years. 
The mean time of drug withdrawal was 13 months. 
Figure 4 illustrates when a second drug was pre- 
scribed. Of the patients who were withdrawn from their 
Order of new anticonvulsant 
Fig. 2: Withdrawal (0) and continuation (m) of the novel 
anticonvulsants in relation to the order of prescription. 
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Fig. 3: The percentage of patients staying on a novel 
anticonvulsant during 1 year starting from the time of 
prescription (I = 0). (-, first-order drug; - - -, 
second-order drug.) 
first drug, 65% (n = 68) received a second novel an- 
ticonvulsant and 23% (n = 82) of the patients who 
stayed on their first drug received a second novel anti- 
convulsant. 
Of the group of patients who continued on the first 
novel drug, 32% (n = 19) stayed on their second novel 
anticonvulsant and 66% (n = 44) of the group who 
were withdrawn from their first drug stayed on their 
second novel anticonvulsant. The introduction of a sec- 
ond novel anticonvulsant gave a significantly poorer 
response when the first drug was not withdrawn (chi- 
squared statistics, P = 0.01). Seventeen percent of 
patients were seizure-free for at least 3 months on their 
first novel anticonvulsant and 8% (n = 63) on their 
second drug. 
Predictors of response 
Drug continuation 
Dichotomous variables, type of seizure disorder, sex, 
psychiatric disorder, learning disability, structural brain 
lesion, neonatal seizures and a family history of 
epilepsy all had no significant influence on drug with- 
drawal. The response rates for patients with a brain le- 
sion, learning disability, psychiatric disorder and par- 
tial or primary generalized seizure disorder are sum- 
marized in Table 1. Table 2 summarizes the mean and 
median values of these variables in the groups of pa- 
tients who stayed on their first new drug and patients 
who were withdrawn from their first novel anticonvul- 
sant. None of the tests comparing age at initiation, age 
at first seizure, the length of seizure disorder at initi- 
ation, seizure frequency, previously used failed drugs 
and total number of drugs used, proved to be signifi- 
cant. Table 3 summarizes the mean and median values 
of these variables in the groups of patients who stayed 
on the first novel anticonvulsant and in those who were 
withdrawn from their first drug. 
Table 1: The distribution of drug continuation and seizure 
freedom within different patient groups. 
% staying 
on the 
n dw % seizure-free 
Psychiatric disorder 21 38 0* 
Brain lesion 53 51 9 
Learning disability 23 70 9 
Family history 31 69 29 
Partial seizures 112 51 11* 
Of all patients, 55% stayed on their first novel anticonvulsant and 
17% became seizure-free. None of the continuation percentages 
proved to differ significantly. * The presence of partial seizures 
and the presence of a psychiatric disorder gave a significantly 
lowerpercenta 
statisttcs P = % 
e of patients becoming seizure-free (&i-squared 
.02 and P = 0.002, res ctively). The mean time 
of follow-up of the patients staying on t e drug was 4.4 years. 7-F 
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Fig. 4: Number and percentages of patients (pt) who received a second novel anticonvulsant in relation to the drug continuation of 
the first and second novel anticonvulsant. The introduction of a second novel anticonvulsant gave a significantly poorer response 
when the first was not withdrawn (chi-squared statistics, P = 0.01). 
Table 2: Mean and median values of patients staying on their first novel anticonvulsant and the patients withdrawn from their first 
novel anticonvulsant. 
Drug withdrawn 
Yes No 
Aee at initiation (vears) 
Mean 
33.1 
Median 
31 
Mean Median 
32.2 27 
Aie at first seiz& (years) 15.0 13.5 14.5 12 
Length of seizure disorder (years) 18.8 18 17.9 16 
Previous failed drugs 2.2 2 2.0 2 
Seizure frequency at initiation (seizures/month) 23.1 9 15.7 5.5 
Total numb& of drugs prescribed 4.4 4 4.1 4 
Statistical analysis did not reveal any significant changes for these factors within responding and non-responding patients (Mann-Whitney 
U-test, P = 0.05). The mean time of follow-up of the patients staying on the drug was 4.4 years. 
Table 3: Mean and median values of patients becoming seizure-free on their first novel anticonvulsant and patients who continue 
to have seizures. 
Seizure freedom 
Age at initiation (years) 
Age at first seizure (years) 
Length of seizure disorder (years) 
Previous failed drugs 
Seizure frequency at initiation (seizures/month) 
Mean 
29.8 
18.8 
10.7 
1.5 
6.5 
Yes No 
Median Mean Median 
26.5 33.6 31 
15 13.9 12 
11* 20.0 19* 
2* 2.2 2* 
1* 22 23; 
Total number of drugs prescribed 3.2 3.5 4.5 4 
*The length of seizure disorder, the seizure Frequency at initiation, the number of previous failed drugs and the total number of drugs 
prescribed were all significantly lower in the group of patients who became seizure-free Mann-Whitney U-test, previous failed drugs 
P = 0.01, all other P-values ~0.001). 
Seizure freedom P = 0.002, respectively). The other dichotomous fac- 
tors, sex, neonatal seizures, brain lesion, learning dis- 
The absence of a psychiatric disorder and the pres- 
ence of a primary generalized seizure disorder gave 
a significantly higher percentage of patients becom- 
ing seizure-free (&i-squared statistics P = 0.02 and 
ability, family history of epilepsy, had no significantly 
different effects on seizure freedom. The presence of 
a positive family history revealed a trend which ap- 
proached significance (P = O.O53).The response rates 
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for these patients are summarized in Table 1. 
The length of seizure disorder, the seizure frequency 
at initiation, the number of previously used failed drugs 
and the total number of drugs prescribed were all sig- 
nificantly lower in the group of patients who became 
seizure-free (previously used failed drugs P = 0.01, 
all other P values t0.001). 
Table 3 summarizes the mean and median values of 
these variables in the groups of patients who still have 
fits and in those who became seizure-free. 
DISCUSSION 
In this study we found no specific factors predicting 
response as defined by drug continuation. For seizure 
freedom, the presence of a psychiatric disorder and 
seizures of partial origin were seen to have a signifi- 
cantly poorer response. The length of seizure disorder, 
seizure frequency at initiation, the number of previ- 
ously used failed drugs and the total number of drugs 
were all significantly lower in the group of patients who 
became seizure-free. 
Our population is representative for patients with 
refractory epilepsy treated in a specialist centre for 
epilepsy. Compared with the general population attend- 
ing an epilepsy clinic, our study population has a higher 
morbidity lo. In a review of a population attending an 
epilepsy clinic, 17% of the patients had what we de- 
fined as a structural brain lesion, 6% a mental handicap 
and 50% of the patients had their seizures controlled 
by regular treatmentlO. 
Our sample of 150 patients proved to be large enough 
to find several discernible effects in the group of 
seizure-free patients, though we must take into account 
that the other effects could be significant in a larger 
population. 
There are several ways of defining response’ ‘. In this 
study we chose seizure freedom and drug continuation, 
as these are two objective and definitive measures of 
success. In contrast to a previous study which found 
that after 6-8 years 27% of the patients were still on 
lamotrigine or vigabatrin and 1% became seizure-free’, 
we found that a higher percentage (55%) of the patients 
continued their first novel anticonvulsant and 17% be- 
came seizure-free. As in this previous study seizure 
freedom was not defined and the morbidity of the pop- 
ulation was ill-defined, we cannot compare our results 
with theirs. Nevertheless, these results appear to indi- 
cate that morbidity is an important factor influencing 
the success of new drugs. 
All the factors which appeared as trends affecting 
drug continuation proved to be more marked and some- 
times significant when applied to our second outcome 
measure, seizure freedom. The presence of a learning 
disability was the only exception to this pattern. For 
with drug continuation, patients with a learning disabil- 
ity had a higher response, whereas their achievement 
of seizure freedom was significantly poorer. We sug- 
gest this discrepancy may relate to the special caring 
situation of these patients. 
The drug continuation of the second novel anticon- 
vulsant was significantly poorer when the first novel 
anticonvulsant was continued. The drug removal curve 
illustrates that the decline in the percentage of patients 
staying on the drug with time is faster in the patients 
receiving a second drug. 
The finding of a poorer response within the group 
of patients with partial epilepsy agrees with a previ- 
ous finding in the general population of patients with 
epilepsy’ l. 
Although we think this retrospective analysis re- 
quires cautious interpretation, it nevertheless provides 
useful information on the prescription of novel anti- 
convulsants in an outpatient setting and shows trends 
which may predict response to the new anticonvulsant 
medications. 
REFERENCES 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
Vigabatrin-a new anticonvulsant. DTB 1990; 28: 95-96. 
Lamotrigine-an add-on epileptic. DTB 1992; 30: 75-76. 
Gabapentin. DTB 1994; 32: 29-30. 
Topiramate-add-on drug for partial seizures. DTB 1996; 34: 
62-64. 
Cockerell, 0. C., Johnson, A. L., Sander, J. W., Hart, Y. M. and 
Shorvon, S. D. Remission of epilepsy: results from the national 
general practice study of epilepsy. Lancer 1995; 346: 140-144. 
Marson, A. G., Kadir, 2. A. and Chadwick, D. W. The new 
antiepileptic drugs: a systematic review of their efficacy and 
tolerability. British Medical Journal 1996; 313: 1169-l 174. 
Marson, A. G., Kadir, 2. A., Hutton, J. L. and Chadwick, D. W. 
The new antiepileptic drugs: a systematic review of their effi- 
cacy and tolerability. Epilepsia 1997; 38: 859-880. 
Walker, M. C., Li, L. M. and Sander, J. W. A. S. Long term use 
of the new antiepileptic drugs, lamotrigine and vigabatrin in 
severe refractory epilepsy. British Medical Journal 1996; 313: 
1184-1185. 
Mignot, G. Drug trials in epilepsy. British Medical Journal 
1996; 313: 1158. 
Tobias, E. S., Brodie, A. F. and Brodie, M. J. An outcome audit 
at the epilepsy clinic: results from 1000 consecutive referrals. 
Seizure 1994; 3: 37-43. 
Walker, M. C. and Sander, J. W. A. S. The impact of new 
antiepileptic drugs on the prognosis of epilepsy: seizure free- 
dom should be the ultimate goal. Neurology 1996; 46: 9 12-914. 
